Resmetirom: First Approval
Drugs · 2024-06 · 84 (6) · 729-735
DOI: 10.1007/s40265-024-02045-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs, online erschienen am 21.05.2024. Verfasst von Susan J Keam. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Drug Approval, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 363-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of metabolic dysfunction associated steatohepatitis (MASH) [previously known as nonalcoholic steatohepatitis (NASH)]. In March 2024, resmetirom was approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in the USA. Resmetirom is also under regulatory review in the EU for the treatment of MASH/NASH. This article summarizes the milestones in the development of resmetirom leading to this first approval for the treatment of adults with MASH/NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Keam, S. J. (2024). Resmetirom: First Approval. Drugs, 84(6), 729-735. https://doi.org/10.1007/s40265-024-02045-0
Vancouver
Keam SJ. Resmetirom: First Approval. Drugs. 2024;84(6):729-735. doi:10.1007/s40265-024-02045-0
BibTeX
@article{Keam2024,
author = {Keam, Susan J},
title = {Resmetirom: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
number = {6},
pages = {729--735},
doi = {10.1007/s40265-024-02045-0}
}
EUVIMED